Company Analysis

GT Biopharma, Inc. (GTBP)

Nasdaq: GTBP · Pharmaceutical Preparations · San Francisco, CA · filing with the SEC since 1995
Grade4.4
◀ Past 3.2● Present 3.1▶ Future 6.2
6 est.

Who runs GT Biopharma, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Breen Michael Martin
CEO and Director. First filing Feb 2021, latest Sep 8, 2025, 1 filing in all.
Officers reporting now
2
of 5 people with a filing in the last fifteen months
Directors reporting now
3
16 people on the record since 2010
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Breen Michael MartinCEO and DirectorFeb 2021Sep 8, 2025none
Urban Alan LouisChief Financial OfficerJun 2022Sep 8, 2025none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Casamento Charles JdirectorMay 2023Sep 8, 2025none
Kramer HilarydirectorJun 2025Sep 8, 2025none
Mun-Gavin David C.directorJul 2025Sep 8, 2025none
Earlier names on the record14, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton GTBP · research, not advice